Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair

GERMANTOWN, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
June 01, 2021 07:30 ET | Source: Orgenesis Inc.

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
May 07, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis First Quarter 2021 Revenue Increases 400% to $9.4 Million Reflecting Initial Success of POCare Platform

Achieves operating profit for the first quarter of 2021 Cash and cash equivalents of $41.8 million as of March 31, 2021 ...
May 06, 2021 07:30 ET | Source: Orgenesis Inc.

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection

IDE approval provides important validation of clinical development plans for the Icellator2 GERMANTOWN, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the...
May 05, 2021 07:30 ET | Source: Orgenesis Inc.

Orgenesis Schedules First Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
March 29, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of Care Cell and Gene Therapy Center

GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
March 18, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Enters into Collaboration Agreement with MIDA to Deploy OMPULs for Point-of-Care Research and Development of Promising Cell and Gene Therapies

GERMANTOWN, Md., March 18, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
March 11, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy

GERMANTOWN, Md., March 11, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
March 09, 2021 07:00 ET | Source: Orgenesis Inc.

Orgenesis Provides Fiscal 2020 Year-End Results and Corporate Update; Expands POCare Therapeutic Pipeline, POCare Technologies, and POCare Network

Revenue increases 96% to $7.7 million for 2020 Projects to more than double in revenue for 2021 based on current contracts already in hand Orgenesis to host conference call today at 8:30AM ET ...
March 08, 2021 07:30 ET | Source: Orgenesis Inc.

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea

GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...